Skip to main content

Anixa Biosciences Inc

ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000715446

In the last 90 days, Anixa Biosciences Inc insiders filed 12 open-market purchases and 0 sales; 63 institutions reported holding it in 13F filings for Q2 2026, worth $15.0M in total; no superinvestor holds it.

Key figures

Insider buysLast 90 days, $321.1K in total
12
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +3 vs. previous quarter
63
13F valueReported value at the end of Q2 2026
$15.0M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ANIX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ANIX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Anixa Biosciences Inc insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 25, 2026 (view filing)8:39 AM ETSep 232 daysTitterton Lewis H jrDirectorPPurchase+49.0K$2.69+$131.9K+4.9%1.05M after
Sep 14, 2026 (view filing)9:45 AM ETSep 104 daysKumar AmitChief Executive OfficerPPurchase+3.00K$2.75+$8.25K+0.5%665.0K after
Sep 14, 2026 (view filing)9:15 AM ETSep 104 daysTitterton Lewis H jrDirectorPPurchase+10.0K$2.73+$27.3K+1.0%997.0K after
Sep 11, 2026 (view filing)8:00 AM ETSep 101 dayKumar AmitChief Executive OfficerPPurchase+5.00K$2.76+$13.8K+0.8%662.0K after
Aug 3, 2026 (view filing)8:45 AM ETJul 313 daysKumar AmitChief Executive OfficerPPurchase+5.00K$3.47+$17.4K+0.8%657.0K after
Jul 28, 2026 (view filing)10:20 AM ETJul 271 dayKumar AmitChief Executive OfficerPPurchase+5.00K$3.44+$17.2K+0.8%652.0K after
Jul 27, 2026 (view filing)3:25 PM ETJul 27Same dayKumar AmitChief Executive OfficerPPurchase+3.19K$3.37+$10.7K+0.5%647.0K after
Jul 27, 2026 (view filing)9:00 AM ETJul 243 daysKumar AmitChief Executive OfficerPPurchase+3.00K$3.73+$11.2K+0.5%643.8K after
Jul 21, 2026 (view filing)10:23 AM ETJul 201 dayKumar AmitChief Executive OfficerPPurchase+5.00K$3.46+$17.3K+0.8%640.8K after
Jul 20, 2026 (view filing)6:19 PM ETJul 20Same dayTitterton Lewis H jrDirectorPPurchase+12.0K$3.47+$41.6K+1.2%987.0K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Anixa Biosciences Inc at the end of Q2 2026; share changes are against Q1 2026.

See all 63 holders
Institutions holding ANIX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Capital Management LLC1,329,852$3.72M0.00%+14,870+1.1%Added
UBS Group AG585,430$1.64M0.00%+33,793+6.1%Added
Laird Norton Trust Company, LLC578,727$1.62M0.03%+12,400+2.2%Added
D.A. Davidson & Co.539,272$1.51M0.01%00.0%Unchanged
Geode Capital Management, LLC359,194$1.01M0.00%−5,537−1.5%Reduced
Marshall Wace, LLP328,332$919.3K0.00%+155,153+89.6%Added
BlackRock, Inc.199,755$559.3K0.00%+29,652+17.4%Added
Vanguard Fiduciary Trust Co192,356$538.6K0.00%+1,282+0.7%Added
State Street Corp159,040$445.3K0.00%00.0%Unchanged
Gsa Capital Partners LLP117,465$329.0K0.02%+18,623+18.8%Added